Description

Braftovi For Sale

What is Braftovi?

Braftovi (encorafenib) is an oral kinase inhibitor that may be used to treat certain types of cancer in combination with other medications. It is approved to treat adults: Braftovi For Sale

• with melanoma skin cancer with a confirmed BRAF V600E or V600K mutation that cannot be treated with surgery or has spread to other parts of the body (metastasized) in combination with binimetinib
• who have had prior treatment for metastatic colorectal cancer with a confirmed BRAF V600E mutation, in combination with cetuximab
• with metastatic non-small cell lung cancer (NSCLC) with a confirmed BRAF V600E mutation in combination with binimetinib.

Braftovi is only used for patients with an abnormal BRAF gene (this is a specific genetic marker). Your doctor will test you for this gene. This medicine is not for treating wild-type BRAF cancers, such as wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.

Braftovi was FDA-approved on June 27, 2018.

Warnings

Although Braftovi is used to treat melanoma, it may increase your risk of developing other types of cancer including skin cancer. Ask your doctor about your specific risk. Tell your doctor if you notice any new skin or other symptoms. Your healthcare provider should check your skin before treatment with Braftovi, every 2 months during treatment, and for up to 6 months after you stop treatment to look for any new skin or other cancers. Braftovi For Sale Online

Braftovi can harm an unborn baby. Do not use it if you are pregnant. Your doctor may conduct a pregnancy test before you start treatment if you are a woman of childbearing age. Use a non-hormonal form of birth control to prevent pregnancy while using Braftovi and for at least 2 weeks after your last dose.

Avoid it in BRAF wild-type tumors because of the risk of increased cell proliferation.

May not be suitable for patients with cardiomyopathy when used in combination with binimetinib. Your healthcare provider will assess your left ventricular ejection fraction (LVEF) before initiating treatment, then after one month of treatment, and then every 2 to 3 months thereafter.

May cause liver toxicity when used in combination with binimetinib. Your healthcare provider will conduct liver function tests before treatment, and then monitor your liver function during treatment.

There is also a risk of major bleeding events, uveitis (inflammation inside the eye), and QT prolongation. Your doctor may perform certain tests before starting treatment, and then monitor you throughout treatment. Electrolyte abnormalities may need correcting before starting Braftovi. Braftovi is not recommended to be used as a single agent.